TAKEDA PHARMACEUTIC-SP ADR (TAK) Stock Overview
NYSE:TAK - US8740602052 - ADR
TAK Key Statistics, Chart & Performance
The current stock price of TAK is 14.99 USD. In the past month the price increased by 5.86%. In the past year, price increased by 0.67%.
TAK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 45.36 | 693.36B | ||
| JNJ | JOHNSON & JOHNSON | 17.72 | 426.69B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 14.48 | 250.88B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18 | 247.73B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.3 | 244.98B | ||
| MRK | MERCK & CO. INC. | 10.92 | 210.11B | ||
| PFE | PFIZER INC | 7.3 | 140.77B | ||
| SNY | SANOFI-ADR | 11.17 | 120.68B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.01 | 96.03B | ||
| GSK | GSK PLC-SPON ADR | 8.8 | 79.92B | ||
| ZTS | ZOETIS INC | 25.14 | 69.31B | ||
| HLN | HALEON PLC-ADR | 20 | 43.93B |
Related stock screener links
About TAK
Company Profile
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 47,455 full-time employees. The firm focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The firm focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The firm operates in Japan, the United States, Europe, and China.
Company Info
TAKEDA PHARMACEUTIC-SP ADR
4F, 2-1-1, Nihombashihon-cho
Chuo-Ku TOKYO-TO 103-8668 JP
CEO: Christophe Weber
Employees: 49281
Phone: 81332782111
TAKEDA PHARMACEUTIC-SP ADR / TAK FAQ
What is the stock price of TAKEDA PHARMACEUTIC-SP ADR today?
The current stock price of TAK is 14.99 USD. The price increased by 0.13% in the last trading session.
What is the ticker symbol for TAKEDA PHARMACEUTIC-SP ADR stock?
The exchange symbol of TAKEDA PHARMACEUTIC-SP ADR is TAK and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is TAK stock listed?
TAK stock is listed on the New York Stock Exchange, Inc. exchange.
What is the price forecast or stock price prediction for TAKEDA PHARMACEUTIC-SP ADR stock?
20 analysts have analysed TAK and the average price target is 17.32 USD. This implies a price increase of 15.55% is expected in the next year compared to the current price of 14.99. Check the TAKEDA PHARMACEUTIC-SP ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TAKEDA PHARMACEUTIC-SP ADR worth?
TAKEDA PHARMACEUTIC-SP ADR (TAK) has a market capitalization of 47.34B USD. This makes TAK a Large Cap stock.
How many employees does TAKEDA PHARMACEUTIC-SP ADR have?
TAKEDA PHARMACEUTIC-SP ADR (TAK) currently has 49281 employees.
What are the support and resistance levels for TAKEDA PHARMACEUTIC-SP ADR (TAK) stock?
TAKEDA PHARMACEUTIC-SP ADR (TAK) has a support level at 14.83 and a resistance level at 15.14. Check the full technical report for a detailed analysis of TAK support and resistance levels.
Is TAKEDA PHARMACEUTIC-SP ADR (TAK) expected to grow?
The Revenue of TAKEDA PHARMACEUTIC-SP ADR (TAK) is expected to decline by -0.85% in the next year. Check the estimates tab for more information on the TAK EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy TAKEDA PHARMACEUTIC-SP ADR (TAK) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TAK, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TAK, evaluating the profitability, health, valuation and growth aspects
- TAKEDA PHARMACEUTIC-SP ADR (TAK) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TAKEDA PHARMACEUTIC-SP ADR (TAK) Sales and EPS estimates to see what analysts future expectations are.
- TAKEDA PHARMACEUTIC-SP ADR (TAK) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TAKEDA PHARMACEUTIC-SP ADR (TAK) Insider and Institutional Ownership to learn about the owners and their transactions.
- TAKEDA PHARMACEUTIC-SP ADR (TAK) Stock Chart to make your own analysis
- TAKEDA PHARMACEUTIC-SP ADR (TAK) Latest news and press-releases to stay up to date.
Does TAKEDA PHARMACEUTIC-SP ADR (TAK) stock pay dividends?
TAKEDA PHARMACEUTIC-SP ADR (TAK) has a dividend yield of 4.51%. The yearly dividend amount is currently 0.65. Check the full fundamental report for a detailed analysis of TAK dividend history, reliability and sustainability.
When does TAKEDA PHARMACEUTIC-SP ADR (TAK) report earnings?
TAKEDA PHARMACEUTIC-SP ADR (TAK) will report earnings on 2025-10-29.
What is the Price/Earnings (PE) ratio of TAKEDA PHARMACEUTIC-SP ADR (TAK)?
The PE ratio for TAKEDA PHARMACEUTIC-SP ADR (TAK) is 51.69. This is based on the reported non-GAAP earnings per share of 0.29 and the current share price of 14.99 USD. Check the full fundamental report for a full analysis of the valuation metrics for TAK.
What is the Short Interest ratio of TAKEDA PHARMACEUTIC-SP ADR (TAK) stock?
The outstanding short interest for TAKEDA PHARMACEUTIC-SP ADR (TAK) is 0.26% of its float. Check the ownership tab for more information on the TAK short interest.
TAK Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to TAK. When comparing the yearly performance of all stocks, TAK is a bad performer in the overall market: 65.87% of all stocks are doing better.
TAK Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to TAK. TAK scores excellent on profitability, but there are concerns on its financial health.
TAK Financial Highlights
Over the last trailing twelve months TAK reported a non-GAAP Earnings per Share(EPS) of 0.29. The EPS decreased by -8.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 3.06% | ||
| ROA | 0.98% | ||
| ROE | 1.99% | ||
| Debt/Equity | 0.6 |
TAK Forecast & Estimates
20 analysts have analysed TAK and the average price target is 17.32 USD. This implies a price increase of 15.55% is expected in the next year compared to the current price of 14.99.
For the next year, analysts expect an EPS growth of 124.68% and a revenue growth -0.85% for TAK